Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Richard B. Lipton; David W. Dodick; David Kudrow; Uwe Reuter; Nadia Tenenbaum; Feng Zhang; Gabriel Paiva da Silva Lima; Denise E. Chou; Daniel D. Mikol

doi:10.1177/03331024211028966

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Richard B. Lipton, David W. Dodick, David Kudrow, Uwe Reuter, Nadia Tenenbaum, Feng Zhang, Gabriel Paiva da Silva Lima, Denise E. Chou, Daniel D. Mikol

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods: This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders. Results: Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo (p < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine (p < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders. Conclusions: Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov,

Original language	English (US)
Pages (from-to)	1458-1466
Number of pages	9
Journal	Cephalalgia
Volume	41
Issue number	14
DOIs	https://doi.org/10.1177/03331024211028966
State	Published - Dec 2021

Keywords

CGRP receptor
Headache
efficacy
headache frequency
monoclonal antibody
pain

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1177/03331024211028966

Cite this

@article{9cdbc9fbd81947ec93b64781acb253e0,

title = "Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies",

abstract = "Background: Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods: This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders. Results: Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo (p < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine (p < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders. Conclusions: Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov,",

keywords = "CGRP receptor, Headache, efficacy, headache frequency, monoclonal antibody, pain",

author = "Lipton, {Richard B.} and Dodick, {David W.} and David Kudrow and Uwe Reuter and Nadia Tenenbaum and Feng Zhang and Lima, {Gabriel Paiva da Silva} and Chou, {Denise E.} and Mikol, {Daniel D.}",

note = "Publisher Copyright: {\textcopyright} International Headache Society 2021.",

year = "2021",

month = dec,

doi = "10.1177/03331024211028966",

language = "English (US)",

volume = "41",

pages = "1458--1466",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "14",

}

TY - JOUR

T1 - Reduction in migraine pain intensity in patients treated with erenumab

T2 - A post hoc analysis of two pivotal randomized studies

AU - Lipton, Richard B.

AU - Dodick, David W.

AU - Kudrow, David

AU - Reuter, Uwe

AU - Tenenbaum, Nadia

AU - Zhang, Feng

AU - Lima, Gabriel Paiva da Silva

AU - Chou, Denise E.

AU - Mikol, Daniel D.

N1 - Publisher Copyright: © International Headache Society 2021.

PY - 2021/12

Y1 - 2021/12

N2 - Background: Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods: This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders. Results: Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo (p < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine (p < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders. Conclusions: Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov,

AB - Background: Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods: This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders. Results: Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo (p < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine (p < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders. Conclusions: Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov,

KW - CGRP receptor

KW - Headache

KW - efficacy

KW - headache frequency

KW - monoclonal antibody

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=85113152600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113152600&partnerID=8YFLogxK

U2 - 10.1177/03331024211028966

DO - 10.1177/03331024211028966

M3 - Article

C2 - 34407654

AN - SCOPUS:85113152600

SN - 0333-1024

VL - 41

SP - 1458

EP - 1466

JO - Cephalalgia

JF - Cephalalgia

IS - 14

ER -

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this